A Trial to Determine the Safety of CC-93269, an Antibody, in People who have Multiple Myeloma That Has Returned After a Period of Treatment And is not Responsive After Treatment.

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506564-14-00

Acronym

CC-93269-MM-001

Enrollment

112

Registered

2023-10-06

Start date

2018-05-16

Completion date

2025-01-15

Last updated

2025-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed and refractory multiple myeloma (RRMM)

None listed

Sex/Gender

All

Age

18 Years to No maximum

Germany, Italy, Spain, Sweden

None listed

Source: EU CTIS · Data processed: Feb 4, 2026